Physician profile
Mitchell M Jacobson
NPI 1346254539
$11,184.51
in general payments reported to CMS, 2019-2025
54 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,390 · 2020: $900 · 2021: $1,685 · 2022: $1,619 · 2023: $1,574 · 2024: $1,725 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,543 · Education: $32.27 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,543.38 |
| Education | $32.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,186.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,581.95 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Sanofi-Aventis U.S. LLC | $635.11 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $633.94 | 2019-2022 | |
| Amgen INC. | $582.05 | 2019-2025 | Evenity, Repatha, Repatha |
| Insulet Corporation | $529.79 | 2019-2024 | Omnipod |
| Dexcom, INC. | $374.11 | 2019-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $345.53 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $331.91 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.06 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novartis Pharmaceuticals Corporation | $274.11 | 2022-2025 | |
| Mannkind Corporation | $237.17 | 2019-2024 | Afrezza |
| Antares Pharma, INC. | $227.17 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Esperion Therapeutics, INC. | $211.69 | 2020-2025 | Nexletol |
| Amneal Pharmaceuticals LLC | $211.66 | 2019-2025 | Unithroid |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.